Diagnostic Performance of the Prostate Cancer Antigen 3 Test in Prostate Cancer: Systematic Review and Meta-analysis

Donghyun Lee; Sung Ryul Shim; Sun Tae Ahn; Mi Mi Oh; Du Geon Moon; Hong Seok Park; Jun Cheon; Jong Wook Kim

doi:10.1016/j.clgc.2020.03.005

Diagnostic Performance of the Prostate Cancer Antigen 3 Test in Prostate Cancer: Systematic Review and Meta-analysis

Donghyun Lee, Sung Ryul Shim, Sun Tae Ahn, Mi Mi Oh, Du Geon Moon, Hong Seok Park, Jun Cheon, Jong Wook Kim

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

Purpose: To explore the diagnostic accuracy of prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer in this systematic review and meta-analysis. Patients and Methods: A systematic literature search of Medline, Embase, and Cochrane Library databases up to October 2019 was performed. The sensitivity, specificity, and diagnostic odds ratio with 95% confidence intervals (CIs) were calculated. The summary receiver operator characteristic graph came from individual studies. We also conducted metaregression analysis to identify the moderated factors. Results: Across 54 studies (17,575 patients), the pooled sensitivity, specificity, and diagnostic odds ratio of PCA3 were 0.71 (95% CI, 0.67-0.74), 0.68 (95% CI, 0.63-0.74), and 5.28 (95% CI, 4.28-6.51), respectively. The area under the summary receiver operator characteristic curve was 0.75 (95% CI, 0.71-0.79). Conclusion: Pooled data indicated that the PCA3 test had moderate sensitivity and specificity in the diagnosis of prostate cancer. PCA3 could be used as a noninvasive method for the diagnosis of prostate cancer. The purpose of this study was to assess the diagnostic accuracy of prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer through a systematic review and meta-analysis of 54 studies. Urinary PCA3 with a cutoff score of 35 had 71% pooled sensitivity and 68% pooled specificity. Urinary PCA3 is a noninvasive biomarker that can be used to aid in the diagnosis of prostate cancer.

Original language	English
Pages (from-to)	402-408.e5
Journal	Clinical Genitourinary Cancer
Volume	18
Issue number	5
DOIs	https://doi.org/10.1016/j.clgc.2020.03.005
Publication status	Published - 2020 Oct

Bibliographical note

Funding Information:
This research was supported by Korea University , Grant number K1924991 . The authors have stated that they have no conflict of interest.

Publisher Copyright:
© 2020 The Author(s)

Keywords

Diagnosis
Meta-analysis
Prostate cancer antigen 3
Prostate-specific antigen
Prostatic neoplasms

ASJC Scopus subject areas

Oncology
Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clgc.2020.03.005

Cite this

@article{2a8ba4899e93417cba2309f874e96b75,

title = "Diagnostic Performance of the Prostate Cancer Antigen 3 Test in Prostate Cancer: Systematic Review and Meta-analysis",

abstract = "Purpose: To explore the diagnostic accuracy of prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer in this systematic review and meta-analysis. Patients and Methods: A systematic literature search of Medline, Embase, and Cochrane Library databases up to October 2019 was performed. The sensitivity, specificity, and diagnostic odds ratio with 95% confidence intervals (CIs) were calculated. The summary receiver operator characteristic graph came from individual studies. We also conducted metaregression analysis to identify the moderated factors. Results: Across 54 studies (17,575 patients), the pooled sensitivity, specificity, and diagnostic odds ratio of PCA3 were 0.71 (95% CI, 0.67-0.74), 0.68 (95% CI, 0.63-0.74), and 5.28 (95% CI, 4.28-6.51), respectively. The area under the summary receiver operator characteristic curve was 0.75 (95% CI, 0.71-0.79). Conclusion: Pooled data indicated that the PCA3 test had moderate sensitivity and specificity in the diagnosis of prostate cancer. PCA3 could be used as a noninvasive method for the diagnosis of prostate cancer. The purpose of this study was to assess the diagnostic accuracy of prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer through a systematic review and meta-analysis of 54 studies. Urinary PCA3 with a cutoff score of 35 had 71% pooled sensitivity and 68% pooled specificity. Urinary PCA3 is a noninvasive biomarker that can be used to aid in the diagnosis of prostate cancer.",

keywords = "Diagnosis, Meta-analysis, Prostate cancer antigen 3, Prostate-specific antigen, Prostatic neoplasms",

author = "Donghyun Lee and Shim, {Sung Ryul} and Ahn, {Sun Tae} and Oh, {Mi Mi} and Moon, {Du Geon} and Park, {Hong Seok} and Jun Cheon and Kim, {Jong Wook}",

note = "Funding Information: This research was supported by Korea University , Grant number K1924991 . The authors have stated that they have no conflict of interest. Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2020",

month = oct,

doi = "10.1016/j.clgc.2020.03.005",

language = "English",

volume = "18",

pages = "402--408.e5",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Diagnostic Performance of the Prostate Cancer Antigen 3 Test in Prostate Cancer

T2 - Systematic Review and Meta-analysis

AU - Lee, Donghyun

AU - Shim, Sung Ryul

AU - Ahn, Sun Tae

AU - Oh, Mi Mi

AU - Moon, Du Geon

AU - Park, Hong Seok

AU - Cheon, Jun

AU - Kim, Jong Wook

N1 - Funding Information: This research was supported by Korea University , Grant number K1924991 . The authors have stated that they have no conflict of interest. Publisher Copyright: © 2020 The Author(s)

PY - 2020/10

Y1 - 2020/10

N2 - Purpose: To explore the diagnostic accuracy of prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer in this systematic review and meta-analysis. Patients and Methods: A systematic literature search of Medline, Embase, and Cochrane Library databases up to October 2019 was performed. The sensitivity, specificity, and diagnostic odds ratio with 95% confidence intervals (CIs) were calculated. The summary receiver operator characteristic graph came from individual studies. We also conducted metaregression analysis to identify the moderated factors. Results: Across 54 studies (17,575 patients), the pooled sensitivity, specificity, and diagnostic odds ratio of PCA3 were 0.71 (95% CI, 0.67-0.74), 0.68 (95% CI, 0.63-0.74), and 5.28 (95% CI, 4.28-6.51), respectively. The area under the summary receiver operator characteristic curve was 0.75 (95% CI, 0.71-0.79). Conclusion: Pooled data indicated that the PCA3 test had moderate sensitivity and specificity in the diagnosis of prostate cancer. PCA3 could be used as a noninvasive method for the diagnosis of prostate cancer. The purpose of this study was to assess the diagnostic accuracy of prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer through a systematic review and meta-analysis of 54 studies. Urinary PCA3 with a cutoff score of 35 had 71% pooled sensitivity and 68% pooled specificity. Urinary PCA3 is a noninvasive biomarker that can be used to aid in the diagnosis of prostate cancer.

AB - Purpose: To explore the diagnostic accuracy of prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer in this systematic review and meta-analysis. Patients and Methods: A systematic literature search of Medline, Embase, and Cochrane Library databases up to October 2019 was performed. The sensitivity, specificity, and diagnostic odds ratio with 95% confidence intervals (CIs) were calculated. The summary receiver operator characteristic graph came from individual studies. We also conducted metaregression analysis to identify the moderated factors. Results: Across 54 studies (17,575 patients), the pooled sensitivity, specificity, and diagnostic odds ratio of PCA3 were 0.71 (95% CI, 0.67-0.74), 0.68 (95% CI, 0.63-0.74), and 5.28 (95% CI, 4.28-6.51), respectively. The area under the summary receiver operator characteristic curve was 0.75 (95% CI, 0.71-0.79). Conclusion: Pooled data indicated that the PCA3 test had moderate sensitivity and specificity in the diagnosis of prostate cancer. PCA3 could be used as a noninvasive method for the diagnosis of prostate cancer. The purpose of this study was to assess the diagnostic accuracy of prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer through a systematic review and meta-analysis of 54 studies. Urinary PCA3 with a cutoff score of 35 had 71% pooled sensitivity and 68% pooled specificity. Urinary PCA3 is a noninvasive biomarker that can be used to aid in the diagnosis of prostate cancer.

KW - Diagnosis

KW - Meta-analysis

KW - Prostate cancer antigen 3

KW - Prostate-specific antigen

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85082936706&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2020.03.005

DO - 10.1016/j.clgc.2020.03.005

M3 - Article

AN - SCOPUS:85082936706

SN - 1558-7673

VL - 18

SP - 402-408.e5

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 5

ER -

Diagnostic Performance of the Prostate Cancer Antigen 3 Test in Prostate Cancer: Systematic Review and Meta-analysis

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this